3350.SG,0P0001N782,0 (3350.SG)

1.4000

+0.0600

+(4.48%)

As of July 23 at 10:00:00 PM GMT+2. Market Open.

Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders

Aadi Bioscience, Inc. (NASDAQ: AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025.

PR Newswire 6 hours ago

AADI
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference

Aadi Bioscience, Inc. (NASDAQ: AADI) announced today its presentation at the TD Cowen 45th Annual Healthcare Conference, taking place March 3-5, 2025, in Boston, MA. Dave Lennon, PhD, CEO, will present a company overview on Monday, March 3, 2025, from 9:50 – 10:20 AM ET.

PR Newswire 7 days ago

AADI
3 US Penny Stocks With Market Caps Over $30M To Watch

After two days of record highs, the U.S. stock market saw a decline with major indices like the Dow Jones and Nasdaq posting losses. In such fluctuating conditions, investors often look for opportunities in various segments of the market, including penny stocks. Although considered an outdated term, penny stocks still represent smaller or newer companies that can offer both affordability and growth potential when backed by strong financials.

Simply Wall St. 10 days ago

AADI

PODC
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced the appointment of David Dornan, PhD as the Company's Chief Scientific Officer (CSO). Dr. Dornan contributes more than two decades of experience in oncology drug discovery and development, with deep expertise in antibody-drug conjugates (ADCs) and other targeted cancer therapies.

PR Newswire 13 days ago

AADI
Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025

Aadi Bioscience, Inc. (NASDAQ: AADI) ("Aadi" or the "Company") announced it filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") on January 31, 2025, and today mailed its definitive proxy statement and a letter to stockholders, in connection with the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") which is scheduled to be held on February 28, 2025.

PR Newswire 25 days ago

AADI
Aadi Bioscience Leads 3 Promising US Penny Stocks

As the U.S. stock market navigates a challenging week marked by encouraging inflation data yet overall losses, investors are exploring diverse opportunities to mitigate risk and capitalize on potential gains. Penny stocks, often associated with smaller or newer companies, continue to attract attention due to their potential for significant returns when backed by strong financial health. Despite being considered a niche area of investment today, these stocks can offer intriguing opportunities...

Simply Wall St. 2 months ago

AADI

IMRX

QD
Aadi Bioscience’s Strategic Agreements and Funding Moves

An announcement from Aadi Bioscience ( (AADI) ) is now available. Aadi Bioscience has entered into a Stock Purchase Agreement with KAKEN Pharmaceutical, selling its subsidiary, including the FYARRO business, for $100 million, which will fund operations into late 2028. Additionally, Aadi has secured an exclusive license for three novel ADC assets from WuXi Biologics and announced a $100 million PIPE financing to support the development of these assets, indicating a strategic shift towards leverag

TipRanks 2 months ago

AADI
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. (HANGZHOU DAC), a global leader in ADC innovation.

PR Newswire 2 months ago

AADI
US Penny Stocks Under $90M Market Cap To Watch

As the U.S. stock market takes a breather after a significant post-election rally, investors are assessing their portfolios amid heightened optimism and fluctuating indices. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing investment area despite their vintage name. These stocks can offer growth opportunities at lower price points when backed by solid financials, presenting potential for impressive returns without the typical risks associated...

Simply Wall St. 3 months ago

AADI

SLNG

PODC
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress.

PR Newswire 3 months ago

AADI
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study. The approximately 25 patients in PRECISION1 who are still benefiting from nab-sirol

PR Newswire 6 months ago

AADI
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress.

PR Newswire 6 months ago

AADI
Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 8:30 am EDT (5:30 am PDT) to report second quarter 2024 financial results and provide recent corporate updates.

PR Newswire 6 months ago

AADI
We're Keeping An Eye On Aadi Bioscience's (NASDAQ:AADI) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 6 months ago

AADI
Aadi Bioscience to Participate in the Jefferies Healthcare Conference

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, announced today participation in the Jefferies Healthcare Conference, taking place June 5-6, 2024, in New York. Dave Lennon, Ph.D., President and CEO, will participate in a fireside chat on Wednesday, June 5, 2024, from 2:00 PM – 2:25 PM EDT.

PR Newswire 8 months ago

AADI
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced new nonclinical data demonstrating the significantly higher intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity of nab-sirolimus compared to intravenous and oral mTOR inhibitors in a xenograft model. These data will be available as an abstract and pu

PR Newswire 9 months ago

AADI
Aadi Bioscience, Inc. (NASDAQ:AADI) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aadi Bioscience, Inc. ( NASDAQ:AADI ) missed earnings with its latest quarterly results, disappointing...

Simply Wall St. 9 months ago

AADI
Analysts Just Made A Major Revision To Their Aadi Bioscience, Inc. (NASDAQ:AADI) Revenue Forecasts

Today is shaping up negative for Aadi Bioscience, Inc. ( NASDAQ:AADI ) shareholders, with the analysts delivering a...

Simply Wall St. 9 months ago

AADI
Aadi Bioscience First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience ( NASDAQ:AADI ) First Quarter 2024 Results Key Financial Results Revenue: US$5.35m (down 8.8% from 1Q...

Simply Wall St. 9 months ago

AADI
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

PR Newswire 9 months ago

AADI

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

3350.SG,0P0001N782,0 (3350.SG)

Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders

Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference

3 US Penny Stocks With Market Caps Over $30M To Watch

Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer

Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025

Aadi Bioscience Leads 3 Promising US Penny Stocks

Aadi Bioscience’s Strategic Agreements and Funding Moves

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

US Penny Stocks Under $90M Market Cap To Watch

Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update

Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates

Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update

Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update

We're Keeping An Eye On Aadi Bioscience's (NASDAQ:AADI) Cash Burn Rate

Aadi Bioscience to Participate in the Jefferies Healthcare Conference

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Aadi Bioscience, Inc. (NASDAQ:AADI) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Analysts Just Made A Major Revision To Their Aadi Bioscience, Inc. (NASDAQ:AADI) Revenue Forecasts

Aadi Bioscience First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update